Why release testing has become a lagging indicator, and what replaces it
How transfer-ready characterization reduces rework across scale, site, and phase
Complex biologics are moving faster. Is your CMC strategy ready?
Four readiness pillars. Three executive case studies. One practical framework for reducing CMC uncertainty in complex biologics.
Inside the white paper
FDA’s 2025 biologics approvals point to a clear shift: more engineered modalities, tighter timelines, and less room to resolve CMC uncertainty late.
Learn how CMC teams can strengthen:
Analytical decision-making before release testing becomes the first signal
Process characterization that holds up across scale, site, and phase
Modelling-enabled development to reduce avoidable iteration
Digital continuity so rationale is not lost at transfer
What You'll Learn
Where modelling-enabled development can reduce iteration and improve process decisions
How connected CMC records preserve rationale across handoffs
What executive case studies reveal about throughput, assay validity, yield, and cycle time